---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-058509"
form_type: "8-K"
ticker: "FLGT"
cik: "0001674930"
company_name: "Fulgent Genetics, Inc."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:32:30.794564+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fulgent reports Q3 total revenue $85M, core revenue up 17% to $66M, GAAP loss $0.44/share

## Summary
- Core revenue (ex-COVID) grew 17% YoY to $66M; total revenue $85M including $19M from COVID reimbursements.
- GAAP net loss $13.1M ($0.44 EPS); non-GAAP loss $11.7M ($0.39 EPS) for Q3 2023.
- Adjusted EBITDA was $18.1M; cash from operations $10.2M in the quarter.
- Cash, cash equivalents, and marketable securities totaled $851M as of Sep 30, 2023.
- Fulgent reiterates full-year 2023 core revenue guidance of $260M.

## SEC filing metadata
- accession: 0000950170-23-058509
- form_type: 8-K
- ticker: FLGT
- cik: 0001674930
- company_name: Fulgent Genetics, Inc.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674930/000095017023058509/0000950170-23-058509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674930/000095017023058509/flgt-20231103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-058509
- JSON: https://secwatch.observer/filing/0000950170-23-058509.json
- Plain text: https://secwatch.observer/filing/0000950170-23-058509.txt

## Key facts
- Earnings Releases
  Fulgent Genetics, Inc. reported third quarter ended September 30, 2023 results: revenue Total Revenue of $85 million, net income GAAP loss of $13.1 million, or $0.44 per share, EPS GAAP loss of $13.1 million, or $0.44 per share. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2023
  - Revenue: Total Revenue of $85 million
  - Net income: GAAP loss of $13.1 million, or $0.44 per share
  - EPS: GAAP loss of $13.1 million, or $0.44 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2023. Third Quarter 2023 Results: • Total Revenue of $85 million • Core Revenue 1 grew 17% year-over-year to $66 million • GAAP loss of $13.1 million, or $0.44 per share • Non-GAAP loss of $11.7 million, or $0.39 per share • Adjusted EBITDA of $18.1 million • Generated cash flow from operations of $10.2 million • Cash, cash equivalents, and investments in marketable securities of $851 million as of September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674930/000095017023058509/0000950170-23-058509-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.